

Global Fibrate Drugs Market Size, Share And Growth Analysis For 2024-2033

The Business Research Company's Fibrate Drugs Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, July 16, 2024 /EINPresswire.com/ -- The fibrate drugs market has experienced robust growth in recent years, expanding from \$3.36 billion in 2023 to



\$3.53 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to emergence of lipid management, cholesterol management focus, clinical research and trials, cardiovascular risk reduction, combination therapies.



You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs

,,

The Business Research
Company

Strong Future Growth Anticipated

The fibrate drugs market is projected to continue its strong growth, reaching \$4.45 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to evolving treatment guidelines, focus on residual risk, precision medicine advancements, innovation in drug delivery.

Explore Comprehensive Insights Into The Global Fibrate Drugs Market With A Detailed Sample Report:

https://www.thebusinessresearchcompany.com/sample_request?id=11932&type=smp

Growth Driver Of The Fibrate Drugs Market

The increased incidence of cardiac diseases is expected to propel the growth of the fibrate drug market going forward. Cardiac diseases encompass a range of conditions affecting both the heart and the blood vessels. It includes coronary heart disease, congenital heart disease, and others. Fibrates are used as a treatment to prevent further heart attacks and strokes in people who already have the condition of their circulatory system, resulting in driving the fibrate drug market.

Explore The Report Store To Make A Direct Purchase Of The Report: https://www.thebusinessresearchcompany.com/report/fibrate-drugs-global-market-report

Major Players And Market Trends

Key players in the fibrate drugs market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Bristol-Myers Squibb Co, Abbott Laboratories, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co Ltd., Fresenius Kabi AG, Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd., Natco Pharma, Hetero Drugs Ltd.

<u>Major companies operating in the fibrate drugs market</u> are focusing on integrating digital health solutions for cardiovascular diseases. Healthcare providers are increasingly prescribing combinations of fibrates with other lipid-lowering agents, such as statins, to achieve synergistic effects and address multiple facets of dyslipidemia.

Segments:

- 1) By Drug Type: Clofibrate, Fenofibrates, Fenofibric Acids, Gemfibrozil, Other Drugs
- 2) By Indication: Hypercholesterolemia, Heart Attacks, Other Indications
- 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
- 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Geographical Insights: North America Leading The Market

North America was the largest region in the fibrate drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding healthcare facilities and increasing awareness of the benefits of fibrate drugs.

Fibrate Drugs Market Definition

Fibrate drugs are prescription drugs that reduce triglyceride levels and raise high-density lipoprotein (HDL) cholesterol levels. Fibrate drugs are used to treat hypercholesterolemia or mixed dyslipidemia.

The main types of fibrate drugs are clofibrate, fenofibrates, fenofibric acids, gemfibrozil, and others. Clofibrate, classified as a fibric acid derivative, is utilized to manage hypertriglyceridemia and raised cholesterol levels. Its principal role is to help regulate and control elevated levels of cholesterol and triglycerides. The fibrate drugs are used to treat hypercholesterolemia, heart attacks, and other that are sold at hospital pharmacies, online pharmacies, and retail pharmacies. The end-users of fibrate drugs include hospitals, homecare, specialty clinics, and others.

Fibrate Drugs Global Market Report 2024 from THE BUSINESS RESEARCH COMPANY covers the

following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Fibrate Drugs Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on fibrate drugs market size, fibrate drugs market drivers and trends, fibrate drugs market major players, fibrate drugs competitors' revenues, fibrate drugs market positioning, and fibrate drugs market growth across geographies. The fibrate drugs market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Drug Delivery Devices Global Market Report 2024
https://www.thebusinessresearch.company.com/report/drug-delivery-devices-global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Drugs for Immunotherapy Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708

Asia: +91 8897263534 Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/727944968

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.